India

HOLD (previously REDUCE)

Consensus ratings*: Buy 7	Hold 1 Sell 9
Current price:	Rs1,611
Target price:	Rs1,768
Previous target:	Rs1,768
Up/downside:	9.7%
InCred Research / Consensus	-0.8%
Reuters:	
Bloomberg:	GLAND IN
Market cap:	US\$3,655m
	Rs265,399m
Average daily turnover:	US\$11.0m
	Rs796.9m
Current shares o/s:	164.7m
Free float: *Source: Bloomberg	42.1%

Key changes in this note

- Upgrade the stock's rating to HOLD (from **REDUCE** earlier).
- FY25F EPS estimate reduced by 10%.



	(-)	(= =)	x -	<i>'</i>
Major shareholders			% held	ł
Promoters			57.9	9
Mirae MF			5.6	3
Nippion			5.3	3

Research Analyst(s)



Praful BOHRA T (91) 22 4161 1552 E praful.bohra@incredresearch.com Yogesh SONI T (91) 22 4161 1566 E yogesh.soni@incredresearch.com

Pharmaceuticals | India | November 05, 2024

Gland Pharma Ltd

Cenexi drag remains; better risk-reward ratio

- 2QFY25 revenue was in line with expectations, but EBITDA was 22% above our estimate, led by a sharp 500bp QoQ growth in base business margin.
- Cenexi should see positive EBITDA in 4QFY25F and FY26F. Management expects Cenexi to deliver EUR200m+ revenue in FY26F.
- Upgrade the stock's rating to HOLD (from REDUCE earlier) with an unchanged target price of Rs1,768.

Healthy base biz, weak Cenexi performance drags overall 2Q results

Gland Pharma's (GPL) 2QFY25 base business (ex-Cenexi) revenue/EBITDA saw healthy QoQ growth (5%/24%), which was 22% above our estimate/in line with the Bloomberg consensus estimate, respectively. Cenexi's revenue was in line with our expectation, with revenue at Rs3.4bn and EBITDA loss at Rs685m. Excluding Cenexi, GPL witnessed a strong sequential growth in India, RoW and other core markets. The US business declined by 2% QoQ, despite a healthy volume growth of 5% YoY/QoQ from new product launches. Cenexi is expected to close FY25F with an EUR160-165m topline and EBITDA break-even by 4QFY25F.

Ex-Cenexi EBITDA margin healthy at 34%

The ex-Cenexi EBITDA margin stood at 34% (vs. 29% in 1QFY25) while Cenexi reported an EBITDA loss of Rs685m (Rs286m loss in 1QFY25) due to plant shutdown. Cenexi's gross margin declined to 69% from 78% in 1QFY25 (and 77% in 2QFY24) due to low uptick at the Belgium plant and an adverse product mix. The base business gross margin improved to 56% from 53% in 1QFY25. The milestone income reduced to 7% (from 10%/16% in 1QFY25/4QFY24, respectively); on the other hand, the profit share proportion declined slightly to 8%. Gland Pharma expects its FY25F base business to grow in low double digits (vs. earlier guidance of mid-teen growth).

Cenexi ramp-up to largely reflect from FY26F

Gland Pharma expects a gradual ramp-up in Cenexi revenue in FY25F, although FY26F should see normalization of revenue back to the EUR50m/quarter run-rate. This should drive better operating leverage and thus, support margin expansion; management gave guidance of a positive EBITDA in 4QFY25F and neutral or low single-digit EBITDA in FY26F. On a medium-term basis, post completion of capex cycle at Cenexi, the asset turn ratio should reach 1-1.25x from 0.8x.

Upgrade to HOLD rating on the stock

Gland Pharma has underperformed the BSE Healthcare Index by almost 28% in the last six months on concerns relating to Cenexi. We now upgrade the stock's rating to HOLD (from REDUCE earlier) due to the favourable risk-reward ratio scenario. Our FY25F EPS stands reduced by 10% while FY26F EPS and the target price of Rs1,768 remain unchanged. The faster-than-expected ramp-up at Cenexi is a key upside risk & vice versa.

Financial Summary	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue (Rsm)	44,007	36,246	56,648	62,299	72,507
Operating EBITDA (Rsm)	15,102	10,248	13,331	14,395	19,265
Net Profit (Rsm)	12,117	7,811	7,725	8,700	13,041
Core EPS (Rs)	73.6	50.0	46.9	52.8	79.2
Core EPS Growth	21.5%	(32.1%)	(6.1%)	12.6%	49.9%
FD Core P/E (x)	21.90	32.24	34.34	30.49	20.34
DPS (Rs)	0.0	0.0	0.0	0.0	0.0
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
EV/EBITDA (x)	15.42	22.21	18.76	17.08	12.37
P/FCFE (x)	25.03	52.32	45.53	29.26	18.66
Net Gearing	(45.3%)	(47.3%)	(17.4%)	(20.3%)	(24.8%)
P/BV (x)	3.71	3.33	3.04	2.77	2.43
ROE	18.6%	10.9%	9.3%	9.5%	12.7%
% Change In Core EPS Estimates				(10.43%)	(0.28%)
InCred Research/Consensus EPS (x)					

Conference-call highlights

- Gland Pharma's biologics facility at Genome Valley has entered into a partnership with Dr. Reddy's Laboratories for the biologics CDMO business. The facility has 8,000L of mammalian capacity and the current utilization rate is 30%.
- The company has inked CDMO contracts for GLP products with three customers.

Figure 1: Financial results su	ummary										
(Rs m)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	Y-o-Y (%)	Q-o-Q (%)
Revenue	10,444	9,383	7,850	12,087	13,734	15,452	15,375	14,017	14,058	2%	0%
Consumption of raw materials	5,195	4,271	3,648	4,529	5,216	5,992	5,994	5,643	5,755	10%	2%
as % of sales	49.7%	45.5%	46.5%	37.5%	38.0%	38.8%	39.0%	40.3%	40.9%		
Employee costs	1,013	1,011	1,028	2,550	3,050	3,453	3,516	3,555	3,298	8%	-7%
as % of sales	9.7%	10.8%	13.1%	21.1%	22.2%	22.3%	22.9%	25.4%	23.5%		
R&D costs	414	512	678	457	351	530	436	489	493	40%	1%
as % of sales	4.0%	5.5%	8.6%	3.8%	2.6%	3.4%	2.8%	3.5%	3.5%		
Other expenditure	854	693	811	1611	1877	1912	1842	1686	1542	-18%	-9%
as % of sales	8.2%	7.4%	10.3%	13.3%	13.7%	12.4%	12.0%	12.0%	11.0%		
EBITDA	2,969	2,896	1,684	2,940	3,241	3,564	3,587	2,644	2,971	-8%	12%
Margin (%)	28.4%	30.9%	21.5%	24.3%	23.6%	23.1%	23.3%	18.9%	21.1%		
Depreciation	367	376	376	653	813	1,053	926	920	938		
Other income	656	615	389	375	532	374	421	514	597		
Interest	17	26	22	49	60	53	100	56	61		
PBT	3,241	3,109	1,676	2,613	2,899	2,832	2,982	2,182	2,568	-11%	18%
Total tax	828	789	325	672	958	913	1,058	745	932		
Tax rate (%)	25.6%	25.4%	19.4%	25.7%	33.0%	32.2%	35.5%	34.1%	36.3%		
PAT before MI	2,412	2,319	1,351	1,941	1,941	1,919	1,924	1,438	1,635	-16%	14%
Minority interest (MI)	0	0	0	0	0	0	0	0	0		
Adj. PAT before extraordinary items	2,412	2,319	1,351	1,941	1,941	1,919	1,924	1,438	1,635	-16%	14%
Extraordinary expenses	0	0	-565	0	0	0	0	0	0		
Reported PAT	2,412	2,319	786	1,941	1,941	1,919	1,924	1,438	1,635	-16%	14%
No. of shares	165	165	165	165	165	165	165	165	165		
EPS	14.6	14.1	8.2	11.8	11.8	11.6	11.7	8.7	9.9		

Figure 2: Margin profile											
Margins (%)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	Y-o-Y (bp)	Q-o-Q (bp)
Gross	50%	54%	54%	63%	62%	61%	61%	60%	59%	-296	-68
EBITDA	28%	31%	21%	24%	24%	23%	23%	19%	21%	-247	227
Adj.PAT	23%	25%	17%	16%	14%	12%	13%	10%	12%	-250	138
Effective tax rate	26%	25%	19%	26%	33%	32%	35%	34%	36%	326	219
								SOURCE: INCF	RED RESEAR	CH, COMPA	NY REPORTS


2QFY23 7,475	3QFY23	4QFY23	1QFY24	205724						
7,475	0.000		1941124	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	Y-o-Y (%)	Q-0-Q (%)
	6,626	5,498	6,602	7,531	8,680	9,621	8,125	8,127	8%	0%
71.6%	70.6%	70.0%	54.6%	54.8%	56.2%	62.6%	58.0%	57.8%		
2,243	1,943	1,705	1,623	1,738	1,573	1,590	1,481	1,658	-5%	12%
21.5%	20.7%	21.7%	13.4%	12.7%	10.2%	10.3%	10.6%	11.8%		
726	814	647	647	876	761	526	527	874	0%	66%
7.0%	8.7%	8.2%	5.4%	6.4%	4.9%	3.4%	3.8%	6.2%		
0	0	0	3,214	3,588	4,438	3,637	3,883	3,399	-5%	-12%
0.0%	0.0%	0.0%	26.6%	26.1%	28.7%	23.7%	27.7%	24.2%		
10,444	9,383	7,850	12,087	13,734	15,452	15,374	14,016	14,058	2%	0%
	2,243 21.5% 726 7.0% 0 0.0%	2,243 1,943 21.5% 20.7% 726 814 7.0% 8.7% 0 0 0.0% 0.0%	2,243 1,943 1,705 21.5% 20.7% 21.7% 726 814 647 7.0% 8.7% 8.2% 0 0 0 0.0% 0.0% 0.0%	2,243 1,943 1,705 1,623 21.5% 20.7% 21.7% 13.4% 726 814 647 647 7.0% 8.7% 8.2% 5.4% 0 0 0 3,214 0.0% 0.0% 0.0% 26.6%	2,243 1,943 1,705 1,623 1,738 21.5% 20.7% 21.7% 13.4% 12.7% 726 814 647 647 876 7.0% 8.7% 8.2% 5.4% 6.4% 0 0 0 3,214 3,588 0.0% 0.0% 0.0% 26.6% 26.1%	2,243 1,943 1,705 1,623 1,738 1,573 21.5% 20.7% 21.7% 13.4% 12.7% 10.2% 726 814 647 647 876 761 7.0% 8.7% 8.2% 5.4% 6.4% 4.9% 0 0 0 3,214 3,588 4,438 0.0% 0.0% 0.0% 26.6% 26.1% 28.7%	2,243 1,943 1,705 1,623 1,738 1,573 1,590 21.5% 20.7% 21.7% 13.4% 12.7% 10.2% 10.3% 726 814 647 647 876 761 526 7.0% 8.7% 8.2% 5.4% 6.4% 4.9% 3.4% 0 0 0 3,214 3,588 4,438 3,637 0.0% 0.0% 0.0% 26.6% 26.1% 28.7% 23.7% 10,444 9,383 7,850 12,087 13,734 15,452 15,374	2,243 1,943 1,705 1,623 1,738 1,573 1,590 1,481 21.5% 20.7% 21.7% 13.4% 12.7% 10.2% 10.3% 10.6% 726 814 647 647 876 761 526 527 7.0% 8.7% 8.2% 5.4% 6.4% 4.9% 3.4% 3.8% 0 0 0 3,214 3,588 4,438 3,637 3,883 0.0% 0.0% 0.0% 26.6% 26.1% 28.7% 23.7% 27.7% 10,444 9,383 7,850 12,087 13,734 15,452 15,374 14,016	2,243 1,943 1,705 1,623 1,738 1,573 1,590 1,481 1,658 21.5% 20.7% 21.7% 13.4% 12.7% 10.2% 10.3% 10.6% 11.8% 726 814 647 647 876 761 526 527 874 7.0% 8.7% 8.2% 5.4% 6.4% 4.9% 3.4% 3.8% 6.2% 0 0 0 3,214 3,588 4,438 3,637 3,883 3,399 0.0% 0.0% 0.0% 26.6% 26.1% 28.7% 23.7% 27.7% 24.2% 10,444 9,383 7,850 12,087 13,734 15,452 15,374 14,016 14,058	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

Figure 4: Actuals vs estimates					
	Actuals	Incred Est.	Variance (%)	Bloomberg Est.	Variance (%)
Revenue (Rsm)	14,058	13,939	1%	14,216	-1%
EBITDA (Rsm)	2,971	2,444	22%	2,847	4%
Margin (%)	21.1	17.5		20.0	
PAT (Rsm)	1,635	1,406	16%	1,629	0%
			SOUR	CE: INCRED RESEARCH, C	COMPANY REPORTS

Figure 5: Our revised earnings estimates	F	(25F		F	Y26F	
	Old	New	Variance (%)	Old	New	Variance (%)
Revenue (Rsm)	63,649	62,299	-2%	72,507	72,507	0%
EBITDA (Rsm)	15,232	14,395	-5%	19,265	19,265	0%
Margin (%)	23.9	23.1		26.6	26.6	
PAT (Rsm)	9,714	8,700	-10%	13,078	13,041	0%
				SOURCE: INCRED	RESEARCH, CON	IPANY REPORTS

InCred Equities


Pharmaceuticals | India Gland Pharma Ltd | November 05, 2024



InCred Equities

Pharmaceuticals | India Gland Pharma Ltd | November 05, 2024

BY THE NUMBERS



Profit & Loss

(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Net Revenues	44,007	36,246	56,648	62,299	72,507
Gross Profit	22,915	19,392	34,917	38,625	46,042
Operating EBITDA	15,102	10,248	13,331	14,395	19,265
Depreciation And Amortisation	(1,103)	(1,467)	(3,446)	(3,600)	(3,800)
Operating EBIT	13,999	8,780	9,886	10,795	15,465
Financial Income/(Expense)	(52)	(74)	(262)	(200)	(200)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	2,239	2,405	1,702	2,200	2,600
Profit Before Tax (pre-El)	16,186	11,111	11,326	12,795	17,865
Exceptional Items		(565)			
Pre-tax Profit	16,186	10,546	11,326	12,795	17,865
Taxation	(4,069)	(2,735)	(3,601)	(4,094)	(4,823)
Exceptional Income - post-tax					
Profit After Tax	12,117	7,811	7,725	8,700	13,041
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	12,117	7,811	7,725	8,700	13,041
Recurring Net Profit	12,117	8,229	7,725	8,700	13,041
Fully Diluted Recurring Net Profit	12,117	8,229	7,725	8,700	13,041

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
EBITDA	15,102	10,248	13,331	14,395	19,265
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(3,931)	(4,179)	(532)	(3,517)	(5,331)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	(3,263)	(2,429)	(2,832)	(4,094)	(4,823)
Net Interest (Paid)/Received	(52)	(74)	(262)	(200)	(200)
Tax Paid	(5,450)	(4,194)	(4,272)	(6,094)	(7,223)
Cashflow From Operations	7,908	3,640	9,968	6,783	9,110
Capex	(5,217)	(2,208)	(3,892)	(4,500)	(4,000)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments			(10,218)		
Other Investing Cashflow					
Cash Flow From Investing	2,690	1,432	(4,141)	2,283	5,110
Debt Raised/(repaid)					
Proceeds From Issue Of Shares	386	214	5		
Shares Repurchased					
Dividends Paid					
Preferred Dividends					
Other Financing Cashflow	(646)	3,573	(15,176)	2,000	2,400
Cash Flow From Financing	(260)	3,787	(15,171)	2,000	2,400
Total Cash Generated	2,430	5,219	(19,312)	4,283	7,510
Free Cashflow To Equity	10,598	5,071	5,827	9,066	14,220
Free Cashflow To Firm	10,651	5,146	6,089	9,266	14,420

Pharmaceuticals | India Gland Pharma Ltd | November 05, 2024

BY THE NUMBERS...cont'd

Balance Sheet					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Cash And Equivalents	32,488	37,707	18,394	22,678	30,188
Total Debtors	11,988	8,714	15,587	12,460	14,501
Inventories	11,857	19,453	16,552	22,428	26,103
Total Other Current Assets	2,188	3,133	5,918	4,984	5,801
Total Current Assets	58,521	69,007	56,452	62,549	76,592
Fixed Assets	16,804	17,362	38,302	39,202	39,402
Total Investments					
Intangible Assets	125	117	3,545	3,545	3,545
Total Other Non-Current Assets	2,886	1,290	8,315	8,315	8,315
Total Non-current Assets	19,815	18,769	50,161	51,061	51,261
Short-term Debt	3	6	2,132	2,132	2,132
Current Portion of Long-Term Debt					
Total Creditors	4,629	5,873	8,627	7,928	8,867
Other Current Liabilities	1,189	1,412	3,224	2,220	2,483
Total Current Liabilities	5,820	7,291	13,984	12,281	13,483
Total Long-term Debt	45	33	1,065	1,065	1,065
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	895	864	4,325	4,325	4,325
Total Non-current Liabilities	940	897	5,390	5,390	5,390
Total Provisions					
Total Liabilities	6,760	8,188	19,374	17,671	18,873
Shareholders Equity	71,576	79,587	87,238	95,939	108,980
Minority Interests					
Total Equity	71,576	79,587	87,238	95,939	108,980
Key Ratios					
	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue Growth	27.1%	(17.6%)	56.3%	10.0%	16.4%
Operating EBITDA Growth	16.0%	(32.1%)	30.1%	8.0%	33.8%
Operating EBITDA Margin	34.3%	28.3%	23.5%	23.1%	26.6%
Net Cash Per Share (Rs)	196.97	228.71	92.27	118.27	163.87
BVPS (Rs)	434.58	483.22	529.68	582.50	661.69
Gross Interest Cover	267.05	118.02	37.73	53.97	77.32
Effective Tax Rate	25.1%	25.9%	31.8%	32.0%	27.0%
Net Dividend Payout Ratio					
Accounts Receivables Days	77.54	104.23	78.29	82.16	67.86
Inventory Days	212.92	339.02	302.38	300.50	334.66
Accounts Payables Days	74.72	113.72	121.78	127.62	115.82
ROIC (%)	26.2%	15.4%	9.7%	10.0%	13.4%
ROCE (%)	21.4%	11.6%	11.6%	11.4%	14.6%
Return On Average Assets	17.0%	10.2%	8.1%	8.0%	10.9%

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. While every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which is believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made (information barriers and other arrangements may be established, where necessary, to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short-term views, etc.) that are inconsistent with and reach a different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

Research Analyst or his/her relative(s) or InCred Research Services Private Limited or our associate may have any financial interest in the subject company.

Research Analyst or his/her relatives or InCred Research Services Limited or our associates may have actual or beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report.

Research Analyst or his/her relative or InCred Research Services Private Limited or our associate entities may have any other material conflict of interest at the time of publication of the Research Report.

In the past 12 months, IRSPL or any of its associates may have:

- a) Received any compensation/other benefits from the subject company,
- b) Managed or co-managed public offering of securities for the subject company,
- c) Received compensation for investment banking or merchant banking or brokerage services from the subject company,
- d) Received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company

We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

Research Analyst may have served as director, officer, or employee in the subject company.

We or our research analyst may engage in market-making activity of the subject company.

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based on any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.

Recommendation	Framework
Stock Ratings	Definition:
Add	The stock's total return is expected to exceed 10% over the next 12 months.
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.
	eturn of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net a stock. Stock price targets have an investment horizon of 12 months.
Sector Ratings	Definition:
Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.
Country Ratings	Definition:
Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underweight	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.